FDA Proposes New Guidance to Accelerate Gene Therapies for Rare Diseases
The U.S. Food and Drug Administration (FDA) is shaping new guidance that could significantly speed up the development of gene therapies for rare diseases. This initiative, influenced by scientists in Philadelphia, aims to allow researchers to test a gene therapy platform against a sample of mutations. If successful, this would enable customization for individual patients without requiring a new clinical trial for each specific mutation. The FDA's new Rare Disease Framework Initiative emphasizes integrating patient perspectives early in the drug development cycle, moving away from traditional late-stage feedback. This framework champions the use of cutting-edge science, novel methods, and innovative clinical trial designs, including externally controlled studies, particularly for ultrarare diseases affecting fewer than 1,000 individuals. Under the Rare Disease Evidence Principles (RDEP) program, treatments for these ultrarare conditions may only need evidence from a single-arm trial, supplemented by strong ...
